Carvedilol more than an antihypertensive: new data show efficacy in CHF and MI

Carvedilol is useful in patients with cardiovascular risk factors. Drug Ther Perspect 1993 Aug 2; 2(2): 1–4 Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997 Jul; 54(1): 161–185 Louis WJ, Krum H, Conway EL. A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders. Drug Saf 1994 Aug; 11(2): 86–93 Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94(11): 2807–16 Cohn JN, Fowler MB, Bristow MA, et al. Effect of carvedilol in severe chronic heart failure [abstract]. J Am Coll Cardiol 1996 Feb; 27 Suppl. A: 169A Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800–6 Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996; 94: 2793–9 Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996 May 23; 334: 1349–55 Bristow MR, Gilbert EM, Abraham WT, et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract no. 3879]. Circulation 1996 Oct 15; 94(8) Suppl. I: I–664 Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–80 Oster G, Menzin J, Richner RE et al. Impact of carvedilol therapy for heart failure on costs of cardiovascular-related hospitalisation [abstract]. J Am Coll Cardiol 1997 Feb; 29 Suppl. A: 326A Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. Circulation 1997 Jul 1; 96(1): 183–191 McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993 Feb; 45(2): 232–58 Östergren J, Storstein L, Karlberg BE. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996 Jan; 5: 41–9 Nahrendorf W, Rading A, Steinig G, et al. A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S114–6 Zehender M, Faber T, Schnabel P, et al. Benefits and hazards of carvedilol in unstable angina — a double-blind, placebo-controlled, randomized study [abstract]. Circulation 1995 Oct 15; 92 Suppl. I: I–20 British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar: 74 Agrawal B, Wolf K, Berger A, et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996; 10: 551–5